Check the medicine and its maker
The pharmacy route follows the care decision. It does not replace the assessment or settle which drug is appropriate.
- Ask for the exact product and ingredient names.
- Ask which pharmacy prepares or fills it.
- Check the product claim separately from the pharmacy record.
Separate a product approval from a pharmacy license
FDA’s September 2026 record includes these approved injections. Tirzepatide is used for type 2 diabetes under the Mounjaro name; its Zepbound version is used for long-term weight management. For semaglutide, Ozempic treats type 2 diabetes. Wegovy is approved to reduce weight and help maintain the loss long term. These are examples of their approved uses, not interchangeable treatment choices.
FDA means the Food and Drug Administration. A product approval concerns a specific medicine. A pharmacy license concerns the business filling a prescription. Keep those questions on separate lines in your notes.
To compound a drug is to mix or change it for a person’s specific need instead of supplying a finished factory product.
No FDA approval covers a compounded drug in September 2026. Before sale, the agency does not review its quality, how well it works or whether it is safe.
Ask what change is proposed, why it matters for you and why a manufactured product would not meet the need. A general claim about being custom-made does not answer those questions.
Compare the compounding settings
For a regular pharmacy making medicine for an individual, the federal rules checked in September 2026 require a valid prescription for a named person. This part of the law is called section 503A. It covers preparation by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed doctor. A prescription is one requirement, not the complete test for lawful compounding.
A separate part of the law, section 503B, covers registered businesses that prepare batches of sterile drugs, often for clinics and hospitals. Sterile means free of living germs. Under the rules checked in September 2026, these businesses may prepare drugs without a prescription for a named person.
That exception concerns the business preparing the drug. The federal rule checked in September 2026 still requires a prescription when a prescription medicine is dispensed.
The law calls these businesses outsourcing facilities: clinics and hospitals can have a separate business prepare drugs for them. The name does not mean overseas. Ask which kind of compounder will make the product.
As of September 2026, joining FDA’s outsourcing-facility register was voluntary. It gave no FDA approval or endorsement to a business or its drugs.
Under the September 2026 rules, a registered outsourcing facility must follow federal factory-quality requirements and is subject to FDA inspections on a schedule based on risk. Registration alone does not show that an inspection has been passed.
Each record tells you something different: registration, license and drug approval are separate checks. Ask the service which record backs its claim. Then match the record to those words.
Treat the ingredient question as its own check
Copies of available drugs
Making a copy means preparing a drug that closely matches an available medicine. The September 2026 rules bar regular copying, or copying in excessive amounts, under section 503A. The exception depends on the prescriber finding that a particular change is significant for the named patient. Section 503B separately bars drugs that are essentially copies of approved drugs.
The difference must be about the person’s medical need. For example, ask whether an ingredient needs to be removed because of an allergy. Ask the prescriber to describe the change and the medical reason for it. Write both beside the price.
Retatrutide was still being studied for long-term weight management and lacked FDA approval as of November 3, 2026. The maker’s plan, stated in its October 8, 2026 court filing, was to apply for approval by the end of 2027’s first quarter. That plan does not show that an application was filed or approval granted.
Retatrutide and cagrilintide are substance names that may appear in an online drug offer. In September 2026, FDA said it had not found any condition either could treat safely and effectively. The agency also said federal law did not allow compounding with them.
Withdrawn ingredient requests
The raw material a pharmacy starts with is called a bulk ingredient. FDA gives a content date of April 22, 2026 for this page. It lists requests that people or groups withdrew after asking the agency to consider ingredients for compounding. Its safety concerns remain beside those ingredients.
A nomination is a request to review an ingredient. Withdrawing one does not grant FDA approval. A separate draft from the U.S. Department of Health and Human Services (HHS), announced October 30, 2026, describes conditional limits on enforcement. Ask what the actual record says about the product being proposed.
The draft says HHS does not plan enforcement action against state-licensed pharmacies and physicians who prepare KPV, semax, BPC-157, MOTS-c, epitalon or TB-500 for an individual patient’s prescription, if all conditions are met. It excludes peptide blends and 503B outsourcing facilities; only single-ingredient preparations are covered. Limits on the exact substance and how it is given also apply. The draft is nonbinding and gives no FDA approval. FDA’s 503A bulks list still contained none of the six on November 3, 2026.
Ask who can answer the pharmacy questions
FDA’s pharmacy checks cover state licensing, a proper prescription and a pharmacist who can answer questions.
The pharmacy license record sits with the state board of pharmacy; FDA’s BeSafeRx page links to the state searches.
Get the pharmacy’s actual name before trying the search. Match it with the name you were given, rather than accepting the service’s home-page logo as the answer. Keep a way to reach the pharmacist beside the contact for the prescriber. Ask whom to call about the drug and whom to call about the care plan.